首页> 外文期刊>Materials science & engineering, C. Materials for Biogical applications >Degradable porous drug-loaded polymer scaffolds for localized cancer drug delivery and breast cell/tissue growth
【24h】

Degradable porous drug-loaded polymer scaffolds for localized cancer drug delivery and breast cell/tissue growth

机译:用于局部癌症药物递送和乳腺细胞/组织生长的可降解多孔药物加载的聚合物支架

获取原文
获取原文并翻译 | 示例
           

摘要

This paper presents the results of a combined experimental and analytical study of blended FDA-approved polymers [polylactic-co-glycolic acid (PLGA), polyethylene glycol (PEG) and polycaprolactone (PCL)] with the potential for sustained localized cancer drug release. Porous drug-loaded 3D degradable PLGA-PEG and PLGA-PCL scaffolds were fabricated using a multistage process that involved solvent casting and particulate leaching with lyophilization. The physicochemical properties including the mechanical, thermal and biostructural properties of the drug-loaded microporous scaffolds were characterized. The release of the encapsulated prodigiosin (PG) or paclitaxel (PTX) drug (from the drug-loaded polymer scaffolds) was also studied experimentally at human body temperature (37 degrees C) and hyperthermic temperatures (41 and 44 degrees C). These characteristic controlled and localized in vitro drug release from the properties of the microporous scaffold were analyzed using kinetics and thermodynamic models. Subsequently, normal breast cells (MCF-10A) were cultured for a 28-day period on the resulting 3D porous scaffolds in an effort to study the possible regrowth of normal breast tissue, following drug release. The effects of localized cancer drug release on breast cancer cells and normal breast cell proliferation are demonstrated for scenarios that are relevant to palliative breast tumor surgery for 16 weeks under in vivo conditions. Results from the in vitro drug release show a sustained anomalous (non-Fickian) drug release that best fits the Korsmeyer-Peppas (KP) kinetic model with a non-spontaneous thermodynamic process that leads to a massive decrease in breast cancer cell (MDA-MB-231) viability. Our findings from the animal suggest that localized drug release from drug-based 3D resorbable porous scaffolds can be used to eliminate/treat local recurred triple negative breast tumors and promote normal breast tissue regeneration after surgical resection.
机译:本文介绍了混合FDA批准的聚合物[聚乳酸二乙醇酸(PLGA),聚乙二醇(PEG)和聚己内酯(PCL)的组合实验和分析研究的结果,其潜在持续局部癌症药物释放。使用多级方法制造多孔药物负载的3D可降解PLGA-PEG和PLGA-PCL支架,所述多级方法包括溶剂浇铸和用冻干液体浸出。表征了包括药物负载的微孔支架的机械,热和生物结构性质的物理化学性质。还在人体温(37℃)和高温温度(41和44℃)上实验研究包封的产品素(PG)或紫杉醇(PTX)药物(来自药物负载的聚合物支架)的释放。使用动力学和热力学模型分析从微孔支架的性质的这些特征控制和局部药物释放。随后,培养正常的乳腺细胞(MCF-10A)在所产生的3D多孔支架上培养28天,以研究药物释放后的正常乳腺组织可能的再生。局部癌症药物释放对乳腺癌细胞和正常乳腺细胞增殖的影响是为了在体内条件下与姑息乳腺肿瘤手术相关的情景。体外药物释放的结果显示,持续的异常(非Fickian)药物释放,最适合Korsmeyer-Peppas(KP)动力学模型,其具有非自发的热力学过程,导致乳腺癌细胞的大规模降低(MDA- MB-231)活力。我们从动物的发现表明,来自基于药物的3D可再吸收多孔支架的局部药物释放可用于消除/治疗局部复制的三重阴性乳腺肿瘤,并在手术切除后促进正常的乳房组织再生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号